Efficacy and safety of dutasteride on prostate cancer risk reduction in Asian
men: the results from the REDUCE study.
Author(s): Akaza H, Kanetake H, Tsukamoto T, Miyanaga N, Sakai H, Masumori N, Nakatsu H,
Sagiyama K, Sakamoto S, Endo Y, Yamanouchi T; REDUCE Study Group.
Affiliation(s): Department of Urology, University of Tsukuba, Tsukuba, Japan.
akazah@med.rcast.u-tokyo.ac.jp
Publication date & source: 2011, Jpn J Clin Oncol. , 41(3):417-23
OBJECTIVE: A post hoc analysis of Asian men in the REDUCE study was conducted to
investigate whether the outcomes were in line with those of the overall
population.
METHODS: REDUCE was a 4-year international, multicenter, randomized,
double-blind, placebo-controlled, parallel-group study. Inclusion criteria were
men between 50 and 75 years of age, a serum prostate-specific antigen level of
2.5-10.0 ng/ml (50-60 years) or 3.0-10.0 ng/ml (>60 years), and a single,
negative prostate biopsy (6-12 cores) within 6 months before enrollment. The
primary endpoint was biopsy-detectable prostate cancer. This post hoc analysis
included subjects who were recorded as Asian.
RESULTS: A total of 134 Asians, including 57 Japanese, were randomized to the
study treatment. During the study period, the incidence of prostate cancer in the
placebo and dutasteride groups was 19.6% (11/56) and 9.3% (5/54), respectively
(relative risk reduction, 54%; 95% confidence intervals, -27 to 83%, P = 0.12),
in the Asian subpopulation. Fewer tumors with the Gleason scores of 7-10 and 8-10
were detected among dutasteride-treated men. Although the incidences of
drug-related sexual adverse events were higher in the dutasteride group, only in
rare occasions did they lead to drug discontinuation.
CONCLUSIONS: The incidence of prostate cancer in the dutasteride group was lower
than that in the placebo group, although the difference was not significant.
These results paralleled those for the overall population and support the value
of dutasteride for prostate cancer risk reduction in Asian men with an increased
risk of prostate cancer.
|
